Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma

被引:50
作者
Feller, John K. [1 ]
Yang, Shi [2 ]
Mahalingam, Meera [1 ]
机构
[1] Boston Univ, Sch Med, Dept Dermatol, Dermatopathol Sect, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA
关键词
BRAFV600E; immunohistochemistry; primary cutaneous melanoma; BRAF MUTATIONS; SIGNALING PATHWAY; KRAS MUTATIONS; ACTIVATION; APOPTOSIS; ADENOMAS; POLYPS;
D O I
10.1038/modpathol.2012.168
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The V600E mutation of BRAF has emerged as both an effective biomarker and therapeutic target for select benign and malignant cutaneous and non-cutaneous human tumors and is typically determined using DNA-based techniques that include allele-specific PCR and direct DNA sequencing. Recently however, the development of new antibodies directed against the V600E protein has opened the door for an easier and more efficient strategy for identifying this mutation. Our present aim was to determine the efficacy of one such antibody, anti-B-Raf (V600E), a mouse monoclonal antibody in which the immunogen is a synthetic peptide derived from the internal region of BRAFV600E. A total of 35 cases of primary cutaneous melanoma were evaluated using a combination of DNA-based techniques that included allele-specific PCR and/or direct DNA sequencing and immunohistochemistry. Cases of papillary thyroid carcinomas (n = 5) and colorectal carcinomas (n = 5), known to harbor the BRAFV600E mutation, served as positive controls for the study. DNA analyses revealed that 6 of 35 (17%) cases of the primary cutaneous malignant melanoma possessed the BRAFV600E mutation. For immunohistochemical analyses, cytoplasmic positivity with anti-B-Raf was noted in 7 of 35 (20%) cases of primary melanoma and in all 10 positive controls. Statistical analyses of the data demonstrated that the sensitivity of the immunohistochemistry was 100% and specificity was 97%. Findings from the current study support the potential use of immunohistochemistry as an ancillary screening tool to assess the BRAFV600E mutation status in primary cutaneous melanoma. Modern Pathology (2013) 26, 414-420; doi:10.1038/modpathol.2012.168; published online 5 October 2012
引用
收藏
页码:414 / 420
页数:7
相关论文
共 29 条
[1]   Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm [J].
Abbas, Ossama ;
Mahalingam, Meera .
JOURNAL OF CUTANEOUS PATHOLOGY, 2009, 36 (06) :613-619
[2]   Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia [J].
Andrulis, Mindaugas ;
Penzel, Roland ;
Weichert, Wilko ;
von Deimling, Andreas ;
Capper, David .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (12) :1796-1800
[3]  
[Anonymous], BR J DERMATOL
[4]   Targeting BRAF for patients with melanoma [J].
Arkenau, H-T ;
Kefford, R. ;
Long, G. V. .
BRITISH JOURNAL OF CANCER, 2011, 104 (03) :392-398
[5]   Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases [J].
Capper, David ;
Berghoff, Anna Sophie ;
Magerle, Manuel ;
Ilhan, Ayseguel ;
Woehrer, Adelheid ;
Hackl, Monika ;
Pichler, Josef ;
Pusch, Stefan ;
Meyer, Jochen ;
Habel, Antje ;
Petzelbauer, Peter ;
Birner, Peter ;
von Deimling, Andreas ;
Preusser, Matthias .
ACTA NEUROPATHOLOGICA, 2012, 123 (02) :223-233
[6]   Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody [J].
Capper, David ;
Preusser, Matthias ;
Habel, Antje ;
Sahm, Felix ;
Ackermann, Ulrike ;
Schindler, Genevieve ;
Pusch, Stefan ;
Mechtersheimer, Gunhild ;
Zentgraf, Hanswalter ;
von Deimling, Andreas .
ACTA NEUROPATHOLOGICA, 2011, 122 (01) :11-19
[7]   MSH-6:: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome [J].
Chhibber, Vishesh ;
Dresser, Karen ;
Mahalingam, Meera .
MODERN PATHOLOGY, 2008, 21 (02) :159-164
[8]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[9]   Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7-challenging the concept of dysplastic nevi as precursor lesions? [J].
DeCarlo, Kristen ;
Yang, Shi ;
Emley, Andrew ;
Wajapeyee, Narendra ;
Green, Michael ;
Mahalingam, Meera .
HUMAN PATHOLOGY, 2010, 41 (06) :886-894
[10]   Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712